ABUS
Arbutus Biopharma CorpPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 23 ▲ Arbutus Biopharma reported improved financials for 2025 with a narro…
- May 13 ▲ Arbutus reported Q1 2026 GAAP EPS of $0.87 (diluted), a massive beat…
- Aug 21 ▲ Arbutus Biopharma announced plans to launch a modified Dutch auction…
- Aug 21 Activist stake: Arbutus Announces Intent to Repurchase Up to US$230 Millio…
- Sep 30 ▲ Arbutus Biopharma announced preliminary results of its $230M modifie…
- Sep 30 ▼ Short interest jumps 84.2% to 34.05M
- Oct 1 ▲ Arbutus Biopharma completed its modified Dutch auction tender offer,…
- Oct 1 ▲ Arbutus Biopharma completed a modified Dutch auction tender offer, r…
- Oct 15 ▲ Short interest falls 27.9% to 24.57M
- Oct 22 FDA: Arbutus Announces FDA Clinical Hold is Lifted on IND Appli…
- Oct 22 ▲ Arbutus Biopharma announced that the FDA has lifted the clinical hol…
- Oct 22 ▲ Arbutus Biopharma announced FDA removal of the clinical hold on its…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q3 2026: 22 added (2 new), 17 trimmed or exited.
- Short sellersCOVERING
Short interest −19.0% to 19.89M shares. 9.1 days to cover, ≈13.0% of shares.
- TrendDOWNTREND
9% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BARCLAYS PLC | TRIM | $12.2M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $9.3M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | $6.6M |
| Nuveen, LLC | DOUBLED | $5.6M |
| CITIGROUP INC | TRIM | $2.8M |
| Quadrature Capital Ltd | DOUBLED | $2.3M |
| AMERICAN CENTURY COMPANIES INC | DOUBLED | $842.0K |
| VANGUARD ASSET MANAGEMENT, Ltd | ADD | $575.3K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Nov 2025| Date | Firm | Rating |
|---|---|---|
| Nov 14, 2025 | Chardan Capital MAINTAIN | Buy |
| Aug 11, 2025 | Chardan Capital MAINTAIN | Buy |
| Mar 28, 2025 | Chardan Capital MAINTAIN | Buy |
| Jan 21, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Nov 20, 2024 | Chardan Capital MAINTAIN | Buy |
| Nov 18, 2024 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Sawhney Roger Director Oct 1, 2026 | TO ISSUER | $85.7K |
Androski Lindsay President and CEO Oct 1, 2026 | TO ISSUER | $123.3K |
Beardsley Robert A Director Oct 1, 2026 | TO ISSUER | $89.7K |
Nguyen Tuan Chief Financial Officer Oct 1, 2026 | TO ISSUER | $240.4K |
Roivant Sciences Ltd. Director Oct 1, 2026 | TO ISSUER | $44.8M |
Beardsley Robert A Director Sep 18, 2026 | EXERCISE | $168.1K |
Beardsley Robert A Director Sep 18, 2026 | EXERCISE | $334.1K |
Beardsley Robert A Director Sep 18, 2026 | TAX W/H | $502.2K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $1.4M |
| Next Q | -$0.03 | -$0.03–-$0.03 | -3.7% | $1.4M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | -$0.11 | -$0.11–-$0.11 | +10.5% | $5.7M |
Short side
FINRA· Oct 30, 2026SecBot reports
21 filings · 4 press releases · 10 bullish · 1 bearish · 2 mixed · 8 neutral- NEUTRAL SC 13G/ANov 16, 2026
Two Seas Capital LP filed an amended Schedule 13G disclosing a 4.1% passive stake (8,143,994 shares) in Arbutus Biopharma as of September 30, 2026, down from the prior filing's undisclosed level. The reduction is likely mechanical following Arbutus's $230M tender offer that repurchased 23% of…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Whitefort Capital Management filed an amended Schedule 13G disclosing a 1.6% passive stake (2,451,033 shares) in Arbutus Biopharma as of September 30, 2026, down from the prior filing's undisclosed level. The reduction follows Arbutus's $230M tender offer that repurchased 23% of shares, which…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13GNov 16, 2026
Nomura Holdings disclosed a 7.3% passive stake in Arbutus Biopharma as of September 30, 2026, via its subsidiary Nomura Global Financial Products. This is a new 13G filing for Nomura, adding to the existing passive holders Morgan Stanley (12.2%) and Whitefort Capital.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 12, 2026
Arbutus Biopharma filed an 8-K posting an updated corporate presentation on its website. The…
Monitor for initiation of a Phase 2b trial for imdusiran and for further AB-101 Phase 1 data in cHBV patients. Cash runway should be assessed in next quarterly filing.
All ABUS filing & press-release reports (25)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G reportNov 16, 2026
- 8-K reportNov 12, 2026
- 8-K reportNov 10, 2026
- PRESS-RELEASE reportNov 10, 2026
- INST-CLUSTER reportNov 6, 2026
- 8-K reportOct 22, 2026
- PRESS-RELEASE reportOct 22, 2026
- SC 13G/A reportOct 7, 2026
- SC 13D/A reportOct 5, 2026
- SC TO-I/A reportOct 1, 2026
- PRESS-RELEASE reportOct 1, 2026
- SC TO-I/A reportSep 30, 2026
- PRESS-RELEASE reportSep 30, 2026
- 8-K reportAug 21, 2026
- INST-CLUSTER reportAug 15, 2026
- PRESS-RELEASE reportAug 12, 2026
- 8-K reportAug 12, 2026
- 8-K reportJul 16, 2026
- INST-CLUSTER reportJun 12, 2026
- 8-K reportMay 13, 2026
- PRESS-RELEASE reportMay 13, 2026
- 8-K reportApr 15, 2026
- PRESS-RELEASE reportMar 23, 2026